Zhejiang Medicine Co Ltd
SSE:600216

Watchlist Manager
Zhejiang Medicine Co Ltd Logo
Zhejiang Medicine Co Ltd
SSE:600216
Watchlist
Price: 14.88 CNY 3.62%
Market Cap: ¥14.3B

Operating Margin

13.6%
Current
Improving
by 6%
vs 3-y average of 7.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13.6%
=
Operating Income
¥1.2B
/
Revenue
¥9B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13.6%
=
Operating Income
¥1.2B
/
Revenue
¥9B

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Zhejiang Medicine Co Ltd
SSE:600216
14.3B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Higher than 78% of companies in China
Percentile
78th
Based on 8 544 companies
78th percentile
13.6%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Zhejiang Medicine Co Ltd
Glance View

Market Cap
14.3B CNY
Industry
Pharmaceuticals

Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.

Intrinsic Value
21.56 CNY
Undervaluation 31%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
13.6%
=
Operating Income
¥1.2B
/
Revenue
¥9B
What is Zhejiang Medicine Co Ltd's current Operating Margin?

The current Operating Margin for Zhejiang Medicine Co Ltd is 13.6%, which is above its 3-year median of 7.6%.

How has Operating Margin changed over time?

Over the last 3 years, Zhejiang Medicine Co Ltd’s Operating Margin has increased from 9.7% to 13.6%. During this period, it reached a low of 0.7% on Mar 31, 2024 and a high of 16.6% on Jun 30, 2025.

Back to Top